Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report report published on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group upgraded Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price target on the stock in a report on Thursday, July 11th.

Brainstorm Cell Therapeutics Stock Down 3.8 %

Brainstorm Cell Therapeutics stock opened at $2.00 on Wednesday. Brainstorm Cell Therapeutics has a 52-week low of $1.96 and a 52-week high of $11.89. The company has a market cap of $10.64 million, a price-to-earnings ratio of -0.58 and a beta of 0.33. The firm’s fifty day moving average is $0.66 and its 200 day moving average is $0.53.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). During the same quarter in the prior year, the company posted ($0.27) earnings per share. On average, equities research analysts anticipate that Brainstorm Cell Therapeutics will post -2.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.